Resultados de la búsqueda 441-450 of 2651 for transexamic
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic ...
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
Rochester, Minn., Scottsdale/Phoenix, Ariz. The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the ...
Rochester, Minn. The purpose of this study is to validate novel echocardiographic parameters and algorithms to quantitatively evaluate right ventricular ...
A través de la parte frontal del cuello, los cirujanos hacen un orificio en la tráquea para facilitar la respiración cuando la vía respiratoria habitual ...
Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without ...
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in ...
The purpose of this study is to use Ultrasound surface wave elastography to measure and compare the tissue thickness and elasticity in normal eyes and eyes with ...
This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that has ...
The purpose of this study is to evaluate the effectiveness and safety of tebentafusp-based regimens tebentafusp monotherapy and in combination with ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?